Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
08 Avril 2024 - 2:00PM
Business Wire
- FY23 Investment Brings Program Total to Nearly $55 Million,
Welcoming Eight New Grant Partners
- Company Continues to Advance Equity in Under-Resourced
Communities with a Focus on Nutrition and STEM Education
- Takeda Publishes its Annual U.S. Community Impact Report
Highlighting Program Progress
Takeda (TSE:4502/NYSE:TAK) today announced
the selection of eight new U.S. non-profit organizations as grant
recipients, as part of its $14.6 million commitment to its FY2023
U.S. Corporate Social Responsibility (CSR) program. To create
greater impact and foster equity in under-resourced communities,
the company is focusing its philanthropic efforts on the two areas
of Food is Health and Building STEM (Science, Technology,
Engineering and Math) Foundations and providing larger, multi-year
grants to select nonprofits. Combined with previous investments
since 2021, Takeda’s total contribution to these initiatives now
amounts to $54.1 million.
“By focusing our efforts on Food is Health and Building STEM
Foundations, we are evolving our program to address two areas of
significant need that will help build up communities and narrow
disparities that can prevent people from realizing their full
potential,” said Julie Kim, president of Takeda’s U.S. Business
Unit and U.S. Country Head. “We are excited to continue this
important work with our new partners, collectively striving to
drive long-term impact within our local communities and more
broadly.”
Takeda reviews grant applications for its U.S. CSR program twice
a year. The company partners with local and national organizations
that align with its philanthropic focus areas, actively listening
and valuing their insights and expertise to understand the areas of
greatest need within communities. By leveraging this collaborative
approach, Takeda provides support to address these critical needs
and make a positive impact on people's lives.
Takeda’s FY2023 U.S. CSR Grantees
Strengthening the Connection Between Food and Health for
vulnerable and underserved communities around the country:
- Community Servings – Medically tailored nutrition program and
advancement of policies that prioritize food’s role in public
health
- West End House – Health, nutrition, food access and education
programs
- Open Hand Atlanta – Medically tailored meals for socially
vulnerable individuals
- Project Angel Food – Home delivered medically tailored meals
program for critically ill people
- Northern Illinois Food Bank – Build healthy communities
program
- Greater Chicago Food Depository – Prepared meals program
Building STEM Foundations to promote educational equity
from kindergarten through college:
- Project Scientist – Phased national expansion of STEAM
programming and gender- and race-equitable teacher training through
the Project Scientist Teaching Institute
- Thrive Scholars – STEM pathways (Technology, Engineering and
Life Sciences) support and Boston expansion
Takeda recently published Caring for Tomorrow: 2023 U.S.
Community Impact Report, an annual report that provides a
comprehensive overview of the initiatives and partnerships that are
making a difference in the lives of communities across the country.
Further details on the company’s U.S. CSR, health equity and
diversity, equity and inclusion programs can be found in the
report.
Learn more about Takeda’s U.S. CSR Program and its philanthropic
strategy here. You can find more details about Takeda’s Global CSR
Program here.
About Takeda
Takeda is focused on creating better health for people and a
brighter future for the world. We aim to discover and deliver
life-transforming treatments in our core therapeutic and business
areas, including gastrointestinal and inflammation, rare diseases,
plasma-derived therapies, oncology, neuroscience and vaccines.
Together with our partners, we aim to improve the patient
experience and advance a new frontier of treatment options through
our dynamic and diverse pipeline. As a leading values-based,
R&D-driven biopharmaceutical company headquartered in Japan, we
are guided by our commitment to patients, our people and the
planet. Our employees in approximately 80 countries and regions are
driven by our purpose and are grounded in the values that have
defined us for more than two centuries. For more information, visit
www.takeda.com.
Forward-Looking Statements
This press release and any materials distributed in connection
with this press release may contain forward-looking statements,
beliefs or opinions regarding Takeda’s future business, future
position and results of operations, including estimates, forecasts,
targets and plans for Takeda. Without limitation, forward-looking
statements often include words such as “targets”, “plans”,
“believes”, “hopes”, “continues”, “expects”, “aims”, “intends”,
“ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”,
“estimates”, “projects” or similar expressions or the negative
thereof. These forward-looking statements are based on assumptions
about many important factors, including the following, which could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements: the economic
circumstances surrounding Takeda’s global business, including
general economic conditions in Japan and the United States;
competitive pressures and developments; changes to applicable laws
and regulations, including global health care reforms; challenges
inherent in new product development, including uncertainty of
clinical success and decisions of regulatory authorities and the
timing thereof; uncertainty of commercial success for new and
existing products; manufacturing difficulties or delays;
fluctuations in interest and currency exchange rates; claims or
concerns regarding the safety or efficacy of marketed products or
product candidates; the impact of health crises, like the novel
coronavirus pandemic, on Takeda and its customers and suppliers,
including foreign governments in countries in which Takeda
operates, or on other facets of its business; the timing and impact
of post-merger integration efforts with acquired companies; the
ability to divest assets that are not core to Takeda’s operations
and the timing of any such divestment(s); and other factors
identified in Takeda’s most recent Annual Report on Form 20-F and
Takeda’s other reports filed with the U.S. Securities and Exchange
Commission, available on Takeda’s website at:
https://www.takeda.com/investors/sec-filings-and-security-reports/
or at www.sec.gov. Takeda does not undertake to update any of the
forward-looking statements contained in this press release or any
other forward-looking statements it may make, except as required by
law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this
press release may not be indicative of, and are not an estimate,
forecast, guarantee or projection of Takeda’s future results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408059362/en/
Media: U.S. and International Media Megan Ostrower
megan.ostrower@takeda.com
Takeda Pharmaceutical (NYSE:TAK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Takeda Pharmaceutical (NYSE:TAK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024